AbbVie (ABBV)
(Delayed Data from NYSE)
$194.29 USD
-1.16 (-0.59%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $193.90 -0.39 (-0.20%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$194.29 USD
-1.16 (-0.59%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $193.90 -0.39 (-0.20%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth F Momentum D VGM
Zacks News
AbbVie (ABBV) to Buy Landos to Strengthen Autoimmune Portfolio
by Zacks Equity Research
AbbVie (ABBV) offers to buy Landos Biopharma (LABP) to boost its portfolio in inflammatory and autoimmune disease drugs.
AbbVie (ABBV) Advances While Market Declines: Some Information for Investors
by Zacks Equity Research
AbbVie (ABBV) closed at $178.53 in the latest trading session, marking a +0.04% move from the prior day.
Why AbbVie (ABBV) is a Great Dividend Stock Right Now
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.
3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income
by Zacks Equity Research
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know
by Zacks Equity Research
Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Is First Trust Value Line Dividend ETF (FVD) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FVD
The Zacks Analyst Blog Highlights Mastercard, AbbVie, Salesforce, Thermo Fisher Scientific and Mondelez
by Zacks Equity Research
Mastercard, AbbVie, Salesforce, Thermo Fisher Scientific and Mondelez are included in this Analyst Blog.
AbbVie (ABBV) Exceeds Market Returns: Some Facts to Consider
by Zacks Equity Research
In the most recent trading session, AbbVie (ABBV) closed at $179.66, indicating a +0.66% shift from the previous trading day.
Top Analyst Reports for Mastercard, AbbVie & Salesforce
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Mastercard Incorporated (MA), AbbVie Inc. (ABBV) and Salesforce, Inc. (CRM).
Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks
by Zacks Equity Research
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
Why AbbVie (ABBV) Dipped More Than Broader Market Today
by Zacks Equity Research
In the latest trading session, AbbVie (ABBV) closed at $179.86, marking a -0.59% move from the previous day.
Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock
by Zacks Equity Research
AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks
by Zacks Equity Research
The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
Why AbbVie (ABBV) is a Top Dividend Stock for Your Portfolio
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.
AbbVie (ABBV) Stock Slides as Market Rises: Facts to Know Before You Trade
by Zacks Equity Research
AbbVie (ABBV) closed the most recent trading day at $180.57, moving -0.27% from the previous trading session.
Should First Trust Morningstar Dividend Leaders ETF (FDL) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FDL
How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks
by Zacks Equity Research
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
AbbVie (ABBV) Beats Stock Market Upswing: What Investors Need to Know
by Zacks Equity Research
In the most recent trading session, AbbVie (ABBV) closed at $178.91, indicating a +1.62% shift from the previous trading day.
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
C3.ai's (AI) Stock Is Soaring After Earnings But is it Time to Buy?
by Shaun Pruitt
As one of the more promising artificial intelligence companies, let's see if it's time to buy C3.ai's (AI) stock after revenue and contract growth fuel its post-earnings rally.
Pharma Stock Roundup: FDA Priority Tag to SNY, ABBV Filings, CHMP Nod for AZN, JNJ, MRK
by Kinjel Shah
The FDA grants priority review status to Sanofi's (SNY) and AbbVie's (ABBV) sBLAs for Dupixent and Epkinly, respectively
Is iShares Core High Dividend ETF (HDV) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for HDV
Should First Trust Value Line Dividend ETF (FVD) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FVD
How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks
by Zacks Equity Research
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
Pharma Stock Roundup: Pfizer's Velsipity Receives EU Nod, ABBV Gets New CEO & More
by Kinjel Shah
European Commission approves Pfizer's (PFE) Velsipity ulcerative colitis (UC) pill. AbbVie (ABBV) appoints Robert A. Michael as the new CEO.